Biotech News

Quest Diagnostics Prices $500 Million of Senior Notes

Quest Diagnostics (DGX)Quest Diagnostics2026-06-25 13:46 ESTCompany update

Quest Diagnostics (DGX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is quest-diagnostics.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

DGXQuest Diagnostics2026-06-25 13:46 EST

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics Declares Quarterly Cash Dividend

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026

DGXQuest Diagnostics2026-06-25 13:46 EST

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers

DGXQuest Diagnostics2026-06-25 13:46 EST

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Quest Diagnostics

Quest Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.

Recent company news

DGXQuest Diagnostics2026-06-26 12:04 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

DGXQuest Diagnostics2026-06-26 12:04 EST

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

DGXQuest Diagnostics2026-06-26 12:04 EST

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

DGXQuest Diagnostics2026-06-26 12:04 EST

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

DGXQuest Diagnostics2026-06-26 12:04 EST

Quest Diagnostics Declares Quarterly Cash Dividend

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Diagnostics and Healthcare Services
Location: Secaucus, New Jersey